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Experimental mitochondria-
targeted DNA methylation 
identifies GpC methylation, not 
CpG methylation, as potential 
regulator of mitochondrial gene 
expression
Monique G. P. van der Wijst, Amanda Y. van Tilburg, Marcel H. J. Ruiters  & Marianne G. Rots
Like the nucleus, mitochondria contain their own DNA and recent reports provide accumulating 
evidence that also the mitochondrial DNA (mtDNA) is subjective to DNA methylation. This evidence 
includes the demonstration of mitochondria-localised DNA methyltransferases and demethylases, 
and the detection of mtDNA methylation as well as hydroxymethylation. Importantly, differential 
mtDNA methylation has been linked to aging and diseases, including cancer and diabetes. However, 
functionality of mtDNA methylation has not been demonstrated. Therefore, we targeted DNA 
methylating enzymes (modifying cytosine in the CpG or GpC context) to the mtDNA. Unexpectedly, 
mtDNA gene expression remained unchanged upon induction of CpG mtDNA methylation, whereas 
induction of C-methylation in the GpC context decreased mtDNA gene expression. Intriguingly, in 
the latter case, the three mtDNA promoters were differentially affected in each cell line, while cellular 
function seemed undisturbed. In conclusion, this is the first study which directly addresses the potential 
functionality of mtDNA methylation. Giving the important role of mitochondria in health and disease, 
unravelling the impact of mtDNA methylation adds to our understanding of the role of mitochondria in 
physiological and pathophysiological processes.
For many decades already, the existence of mitochondrial DNA (mtDNA) methylation has been the subject of 
debate1–8. Especially in the early days, the, on average, low level of mtDNA methylation (2–5%)3, 9 may have com-
plicated its detection. Moreover, nuclear contamination of isolated mitochondria and the subsequent detection of 
nuclear integrations of mtDNA (NUMTs) may have distorted the readout. Some recent papers indeed reject the 
existence of mtDNA methylation6, 7. Intriguingly, at the same time, emerging evidence based on a wide variety of 
techniques10, convincingly supports the existence of mtDNA methylation. Such supporting evidence, as reviewed 
by us elsewhere11, includes the discovery of a) a mitochondria-targeted human DNA methyltransferase 1 tran-
script variant (mtDNMT1)12, b) the presence of both CpG and CpH (where H is A, T or C) methylation8, 12–15 and, 
importantly, c) correlations with diseases such as cancer16, Down syndrome17 and diabetes18. Although several 
of these papers hint toward an effect of mtDNA methylation on mitochondrial gene expression12, 16, 18–20, a direct 
causal link has yet to be demonstrated.
Mitochondrial transcription is differently regulated compared to its nuclear counterpart21, and therefore, the 
effect of mtDNA methylation may be different from the effects known for nuclear DNA (nDNA) methylation. 
The mtDNA contains one non-coding region called the D-loop control region. It is within or near this region 
that all three promoters are located: one for the light (L)-strand (LSP), and two for the heavy (H)-strand (HSP1 
and HSP2). The LSP and HSP2 give rise to one polycistronic transcript from the L- or H-strand, respectively. The 
Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen 
(UMCG), Hanzeplein 1, 9713, GZ, Groningen, The Netherlands. Correspondence and requests for materials should 
be addressed to M.G.R. (email: m.g.rots@umcg.nl or m.g.p.van.der.wijst@umcg.nl)
Received: 1 December 2016
Accepted: 14 February 2017
Published: xx xx xxxx
OPEN
www.nature.com/scientificreports/
2Scientific RepoRts | 7: 177  | DOI:10.1038/s41598-017-00263-z
HSP1 gives rise to a short transcript containing rRNA genes (12S and 16S rRNA), whereas LSP and HSP2 encode 
together for 13 protein-coding genes involved in the oxidative phosphorylation (OXPHOS) and 22 transfer RNAs 
(tRNAs) (Fig. 1)22. Resulting from the above, an effect on mitochondrial gene expression is expected to translate 
to dysfunctional OXPHOS.
MtDNA methylation may directly regulate mtDNA gene expression (as described above), or alternatively, 
some suggested that it may do so indirectly23, 24 via the modulation of mtDNA replication13, 15. MtDNA replication 
begins with the transcription of a small (~100 bp) RNA strand (7S RNA) from the LSP. This 7S RNA molecule 
is terminated in the conserved sequence boxes 1–3 and remains bound to the L-strand from which it is synthe-
sised25. This event may initiate the transcription of small stretches of the complementary H-strand around the 
origin of H-strand replication (OH) by the mitochondrial DNA polymerase (POLG), resulting in the formation of 
a short DNA fragment (7S DNA) that together with the mtDNA forms a stable D-loop structure26, 27. Interestingly, 
it is in this region of the D-loop that Bianchessi et al. observed the highest methylation frequency and greatest 
asymmetry of CpG and CpH methylation between both strands15. These findings point to a possible functional 
effect of mtDNA methylation on 7S DNA and/or D-loop formation. The D-loop provides an open DNA struc-
ture28, 29, which may increase the binding of proteins involved in mtDNA replication or transcription. Therefore, 
by affecting the accessibility of the D-loop, D-loop mtDNA methylation may indirectly affect these processes.
Despite recent progress in the field of mtDNA methylation and its possible contribution to disease, clear-cut 
evidence for its functionality is still lacking. Therefore, this study aims to gain insight into functional effects 
of mtDNA methylation, if present at all. We hypothesize that differential mtDNA cytosine methylation affects 
mtDNA gene expression or mtDNA replication, and as such may contribute to the pathogenesis of various dis-
eases14, 16–19. Here, we show that low levels of methylation can be detected in the mtDNA of various cancer cell 
lines and fibroblasts of a mtDNA disease patient. Moreover, we provide the first insights into the possible role of 
both CpG and GpC mtDNA methylation using a mitochondria-targeted bacterial CpG methyltransferase M.SssI 
(MLS-M.SssI)30 and Chlorella virus NYs-1 GpC methyltransferase M.CviPI (MLS-M.CviPI) which methylates 
Cs in the GpC-context, independent of the 3′ neighbouring nucleotide, so including, but not limited to, CpGs31.
Results
Detection of mitochondrial DNA methylation. First, the presence and level of mtDNA methylation 
were determined in two regions that were previously described to be methylated12, 13. For this purpose, bisulfite 
sequencing was performed of a region in the D-loop (Fig. 2a) and mtCOX2 gene (Fig. 2b) in three to four different 
cancer cell lines (HeLa, HCT116, SKOV3 and C33A). As shown in Fig. 2, no mtDNA methylation was detected 
for the majority of analysed CpGs. Nevertheless, 2 out of 4 CpGs in the D-loop region, and 2 out of 17 CpGs in the 
mtCOX2 gene did show DNA methylation, albeit at low levels. In the D-loop region, CpG #2 and/or CpG #4 were 
found to be methylated in C33A and SKOV3, respectively, up to about 3% (1/29 clones) and 17% (5/29 clones) 
(Fig. 2a). A comparable methylation pattern (4% (1/28 clones) methylation at CpG #2, 11% (3/28 clones) meth-
ylation at CpG #4) was found in skin fibroblasts isolated from a patient with a mitochondrial disease (Fig. 2a). In 
Figure 1. Mitochondrial DNA (mtDNA). The human mtDNA is a 16,569 bp circular DNA, containing a heavy 
(H, outer ring) and light (L, inner ring) strand. The genes encoded from the L-strand are written inside the 
circular DNA, whereas genes encoded from the H-strand are written on the outside. The protein-coding genes 
encode for the complexes required for oxidative phosphorylation (Complex I: orange, complex III: purple, 
complex IV: pink, complex V: yellow). The D-loop region contains the promoters for the L- and H-strand  
(LSP, HSP1, HSP2) and the origin of replication of the H-strand (OH).
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the mtCOX2 gene, methylation was detected up to 20% (1/5 clones) for CpG #13 and 8% (1/12 clones) for CpG 
#14 (Fig. 2b). Since several studies show the presence of CpH methylation in the mtDNA13–15, also the level of 
CpH methylation was analysed for our cell lines in both regions. This analysis revealed an average level of CpH 
methylation below 1% (Suppl. Table 1).
Mitochondria-targeted DNA methyltransferases efficiently methylate the mtDNA. Next, we 
addressed the function of mtDNA methylation by inducing methylation via two different approaches. The first 
approach was to reproduce a published disease model (diabetic retinopathy) in which glucose-induced mtDNA 
methylation was observed18. The second approach was to enforce mtDNA methylation by targeting various DNA 
methyltransferases to the mitochondria.
For the first approach, we aimed to reproduce the study of Mishra et al., in which a 4 day high (20 mM) ver-
sus low (5 mM) glucose treatment in bovine retinal endothelial cells was sufficient to induce DNMT1-mediated 
mtDNA methylation in the D-loop (3 fold) and mtCYTB region (1.8 fold), but not in the mtCOX2 region18. For 
this purpose, we exposed a variety of healthy (CiGenCs, IHH, OSE-C2) and cancerous (C33A, HCT116) cell 
lines to high (25 mM) versus low (5 mM) glucose medium for 4 days. Subsequently, methylation of the mtDNA 
in the D-loop, mtCOX2 and mtCYTB region was determined by MeDIP. None of the analysed regions showed 
a differential methylation level upon high versus low glucose treatment (Suppl. Fig. 1). Therefore, we continued 
with our second approach.
For our second approach, we stably expressed mitochondria-targeted DNA methyltransferases, modifying 
cytosine in the CpG context (MLS-M.SssI: bacterial CpG methyltransferase30, MLS-DNMT1: human CpG meth-
yltransferase) or in a different context (MLS-M.CviPI: Nys-1 chorella virus GpCme methyltransferase31, MLS-hM.
CviPII: humanised Nys-1 chorella virus CmeCD methyltransferase32), in C33A and HCT116 cells. Despite using 
previously published12 (and unpublished) primers (Table 1), we could not clone or detect mRNA expression 
of the endogenous mitochondria-targeted DNMT1 variant (mtDNMT1), which precluded its direct use. As 
an alternative, we targeted the normal (non-mitochondria-targeted) DNMT1 gene to the mitochondria using 
our mitochondria-targeting plasmid (MLS-DNMT1). Moreover, since it is unknown which methyltransferase 
may perform CpH methylation of the mtDNA (DNMT1, DNMT3A and DNMT3B have been excluded13), 
mitochondria-targeted viral methyltransferases (MLS-M.CviPI and MLS-hM.CviPII) were used. As a negative 
control, wild-type cells or cells stably expressing the targeting plasmid without effector domain were generated 
(MLS-NoED). These cell lines were chosen because of their differential p53 status (C33A – p53 mutant, HCT116 
– p53 wild-type), as p53 knockdown is known to preferentially activate mtDNMT112. Moreover, the HCT116 cells 
were previously used to show that preferential upregulation of mtDNMT1 (by knockdown of p53) could induce 
expression of mtND1 and repress expression of mtND612.
To confirm efficient methylation of the mtDNA, two regions (D-loop, mtCOX2) in the mtDNA were selected 
for bisulfite sequencing. We could not detect induction of mtDNA methylation using MLS-DNMT1 or hM.Cvi-
PII (data not shown). On the other hand, M.SssI and M.CviPI could both successfully induce mtDNA methyl-
ation (Fig. 3). In the D-loop region, M.SssI induced CpG methylation ranging between 60–100% and 33–67% 
for C33A and HCT116 cells, respectively (Fig. 3a). In the mtCOX2 region, induction of CpG methylation lev-
els varied between 91–100% and 75–100% for C33A and HCT116 cells, respectively (Fig. 3b). These data were 
independently confirmed in the HCT116 cells for three mtDNA regions (D-loop, mtCOX2, mtCYTB) using a 
methylated DNA immunoprecipation (MeDIP) approach. In line with the bisulfite sequencing data, the MeDIP 
showed more efficient methylation of the mtCOX2 gene (~79× induction over IgG) compared to the D-loop 
(~26× induction over IgG) (Suppl. Fig. 1). Moreover, a catalytically inactive double mutant of M.SssI (MLS-M.
SssI ∆∆) was unable to methylate the D-loop (Fig. 3a) or mtCOX2 region (Fig. 3b) of HCT116 cells. This clearly 
Figure 2. Bisulfite sequencing of mtDNA. Bisulfite sequencing of a region in the D-loop (H-strand) (a) and 
mtCOX2 gene (L-strand) (b) for SKOV3, skin fibroblasts of a mtDNA disease patient (only in a) HeLa, HCT116 
and C33A cells (a,b). Each circle represents a single CpG position, the percentage of black of each circle 
represents the percentage of methylation.
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shows that the observed methylation was dependent on the DNA methyltransferase activity of M.SssI. M.CviPI 
also successfully methylated the mtDNA in both the D-loop (Fig. 3c) and mtCOX2 region (Fig. 3d), albeit with 
lower efficiency than M.SssI. In the D-loop, M.CviPI induced GpC methylation varying between 0–36% and 
0–40% for C33A and HCT116 cells, respectively (Fig. 3c). In the mtCOX2 region, induction of GpC methylation 
levels ranged between 0–13% and 0–33% for C33A and HCT116 cells, respectively (Fig. 3d).
Exclusive mitochondrial localization of our mitochondria-targeted plasmid was confirmed by confocal 
microscopy (HCT116 MLS-mCherry-M.SssI) (Fig. 4a) and western blotting (C33A MLS-M.SssI, -M.CviPI and 
HCT116 MLS-M.SssI, -M.SssI ∆∆, -M.CviPI) (Fig. 4b). Moreover, no increase in methylation was observed in a 
hypomethylated nDNA region (GAPDH) (Suppl. Fig. 1). Important to mention is that the mitochondrial expres-
sion of M.SssI or M.CviPI was not associated with any toxicity, which is in contrast to the nuclear expression of 
e.g. M.SssI33 in mammalian cells.
Effect of mtDNA methylation on mtDNA gene expression and copy number. In the nucleus 
DNA methylation is often associated with gene repression. To determine whether this holds true for mtDNA 
methylation, a qRT-PCR was performed on five or six mitochondrial genes: mtND1, mtND6, mtCOX1, mtCYTB, 
12S rRNA and 16S rRNA. These genes were chosen in such a way that at least one gene of each mitochondrial 
promoter was interrogated (Fig. 1), i.e. LSP (mtND6), HSP1 (12S and 16S rRNA) and HSP2 (12S and 16S rRNA, 
mtND1, mtCOX1, mtCYTB). Unexpectedly, M.SssI-induced CpG methylation of the mtDNA did not significantly 
alter the expression of any of the genes tested in either C33A (Fig. 5a) or HCT116 cells (Fig. 5b). In contrast, 
M.CviPI-induced GpC methylation of the mtDNA did significantly repress a number of mitochondrial genes. 
Interestingly, dependent on the cell line, either the HSP1-regulated genes (C33A, Fig. 5c) or the HSP2-regulated 
genes (HCT116, Fig. 5d) were repressed. The effect of M.CviPI was not the result of overexpression of a 






NotI-conII promoter-NotI GGCCGCAGATCCATTATACGAGCCGATGATTAATTGTCAACAGC GGCCGCTGTTGACAATTAATCATCGGCTCGTATAATGGATCTGC
q(RT-)PCR
mtND1 (RtprimerDB) ATACCCCCGATTCCGCTACGAC GTTTGAGGGGGAATGCTGGAGA
mtND651 GGGTGGTGGTTGTGGTAAAC CCCCGAGCAATCTCAATTAC
mtCOX1 (RtprimerDB) CGATGCATACACCACATGAA AGCGAAGGCTTCTCAAATCA
mtCYTB (RtprimerDB) AATTCTCCGATCCGTCCCTA GGAGGATGGGGATTATTGCT
12S rRNA52 CTGCTCGCCAGAACACTACG TGAGCAAGAGGTGGTGAGGT




mtDNMT1 #112 TCCCTGGGCATGGCCGGCT CTCTTTCCAAATCTTGAGCCGC
mtDNMT1 #2 CCTCCCCATCGGTTTCCG CCAAATCTTTGAGCCGCCTG
mtDNMT1 #3 ATGGCCGGCTCCGTTCCA “ ”
β-actin CCAACCGCGAGAAGATGA CCAGAGGCGTACAGGGATAG
mtDNA ratio D-loop TCACCCTATTAACCACTCACGG ATACTGCGACATAGGGTGCTC
nDNA ratio β-actin TGAGTGGCCCGCTACCTCTT CGGCAGAAGAGAGAACCAGTGA
7S DNA primer A + B115 GTGGCTTTGGAGTTGCAGTT CAGCCACCATGAATATTGTAC







BS6_D-loop (H)13 CACATCTCTACCAAACCCC TGGGGTGATGTGAGTTTGTT
BS6_D-loop (L)13 AGAGAGTATATTTTTGTTAAATTTT AGGAAGAGAGACCCATCTAAACATTTTCAA
mtCOX2 (L)7 ATTGGTTATTAATGGTATTGAATTTA CTCCACAAATTTCAAAACATTAAC
Table 1. Primer sequences. Restriction sites are underlined. The 6- to 10-bp tags added to primers are indicated 
in bold.
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mitochondrial targeting construct as no effect on gene expression was observed after targeting the empty vector 
to the mitochondria (MLS-NoED) (Suppl. Fig. 2).
As mitochondrial gene repression can be the effect of a lower number of mtDNA molecules23 (Suppl. Fig. 3), 
we determined whether the effects on gene expression were the result of changes in mtDNA copy number (Fig. 6). 
MtDNA copy number was unchanged in the C33A cells expressing MLS-M.SssI (Fig. 6a) or MLS-M.CviPI 
(Fig. 6c), as well as in the HCT116 cells expressing MLS-M.CviPI (Fig. 6d). Therefore, the effect on gene expres-
sion induced by M.CviPI (Fig. 5c,d) seems to be the direct result of mtDNA methylation. The only condition that 
did result in a reduction of mtDNA copy number was in the HCT116 cells expressing MLS-M.SssI. In this con-
dition, the relative copy number decreased to 0.70 ± 0.06 (p < 0.05) (Fig. 6b). These results were confirmed using 
an independent mitochondrial primer pair amplifying the mtCOX1 region (Suppl. Fig. 3). The effect on mtDNA 
copy number was dependent on the DNA methyltransferase activity of M.SssI, as the catalytically inactive double 
mutant of M.SssI did not affect the mtDNA copy number (Fig. 6b).
To gain insight into the mechanism by which mtDNA methylation may affect mtDNA copy number, we deter-
mined the expression of three nuclear-encoded genes (PGC1α, NRF1, TFAM) involved in the mtDNA biogenesis 
(Fig. 7). In neither the C33A (Fig. 7a) nor the HCT116 (Fig. 7b) cells expressing MLS-M.SssI, gene expression of 
these genes was changed. Therefore, mtDNA methylation is not indirectly regulating the mtDNA copy number 
via the regulation of nuclear-encoded mitochondrial biogenesis genes.
MtDNA methylation has been suggested to play a role in D-loop formation and mtDNA replication13, 15, pos-
sibly via the regulation of 7S DNA primer formation15. To address this, we studied the effect of CpG (Fig. 8a,b) 
Figure 3. Bisulfite sequencing of mtDNA in cells with or without mitochondria-targeted M.SssI or M.CviPI. 
Bisulfite sequencing of a region in the D-loop (H-strand) (a,c) and mtCOX2 gene (L-strand) (b,d) for C33A 
and HCT116 cells expressing a mitochondria-targeted CpG methyltransferase M.SssI (MLS-M.SssI), the 
catalytically inactive double mutant of M.SssI (MLS-M.SssI ∆∆, only for HCT116 cells) or empty vector control 
(MLS-NoED) (a,b), or a mitochondria-targeted GpC methyltransferase M.CviPI or wild-type cells (wt) (c,d). 
Each circle represents a CpG (a,b) or GpC (c,d) position. The percentage of methylation on each position is 
represented in black.
www.nature.com/scientificreports/
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or GpC (Fig. 8c,d) methylation on 7S DNA primer formation in C33A (Fig. 8a,c) and HCT116 (Fig. 8b,d) cells. 
However, as shown in Fig. 8, 7S DNA primer formation was not affected by CpG or GpC methylation.
From the above, it seems that depending on the cell type (C33A vs HCT116, Suppl. Table 2) and context of 
cytosine methylation (CpG vs GpC), mtDNA methylation can play a role in reducing mtDNA gene expression 
(Fig. 5c,d) or mtDNA copy number (Fig. 6b). We wondered whether this would affect any mitochondrial or 
cellular functions in general. First, we tested the effect of CpG (Fig. 9a) and GpC (Fig. 9b) methylation on mito-
chondrial metabolic activity and cell proliferation of the stable cell lines. As becomes clear from those figures, in 
both cell lines, mitochondrial metabolic activity and cell proliferation were unaffected by CpG (Fig. 9a) or GpC 
(Fig. 9b) methylation. As mitochondrial dysfunction is often associated with a change in mitochondrial super-
oxide production34, the production of mitochondrial superoxide was assessed by the mitoSox Red ROS probe. 
Mitochondrial superoxide production also did not change upon induction of CpG (Fig. 9c,d) or GpC (Fig. 9e,f) 
methylation in C33A (Fig. 9c,e) or HCT116 cells (Fig. 9d,f). As we did not observe any downstream effects 
of the mtDNA methylation induced changes on mitochondrial or general functions, we hypothesized that the 
functional effect of mtDNA methylation may only become visible under stress conditions. Since mitochondria 
are major producers of reactive oxygen species (ROS)34, we looked into the effect of nearly complete CpG meth-
ylation on the sensitivity toward ROS-induced cell death in C33A (Fig. 9g) or HCT116 cells (Fig. 9h). Again, this 
function remained unchanged upon induction of CpG methylation.
Discussion
By targeting the CpG methyltransferase M.SssI or the GpC methyltransferase M.CviPI to the mitochondria, we 
could show for the first time that mtDNA methylation might have a direct, be it context-dependent effect: in 
HCT116, but not C33A cells, induction of CpG methylation in the mtDNA resulted in a decrease in mtDNA 
copy number. On the other hand, induction of GpC but not CpG methylation in the mtDNA, in either C33A or 
HCT116 cells, resulted in repression of HSP1- or HSP2-regulated genes, respectively. Interestingly, we could not 
detect any change in mitochondrial (e.g. metabolic activity, mtROS production) or cellular (e.g. cell proliferation, 
sensitivity to apoptosis) functions in general for either type of methylation. So, the exact consequences of these 
effects remain to be discovered.
Figure 4. Mitochondrial localization of mitochondria-targeted DNA methyltransferases. (a) Confocal 
microscopy of HCT116 cells expressing MLS-mCherry-M.SssI. In order to stain the mitochondria, cells were 
incubated at 37 °C for 30 min. with 100 nM Mitotracker Deep Red. (b) Western blot of mitochondria-targeted 
M.CviPI, M.SssI or the catalytically inactive M.SssI ∆∆. Mitochondrial (MER) and nuclear (NER) protein 
extracts were isolated from C33A cells expressing mitochondria-targeted M.CviPI (lane 1) or M.SssI (lane 5)  
and HCT116 cells expressing mitochondria-targeted M.CviPI (lane 2), M.SssI (lane 3) or M.SssI ∆∆ (lane 4).  
A HAtag antibody was used to recognize the mitochondria-targeted constructs in the MER (49 kDa for 
M.CviPI, 52 kDa for M.SssI) or NER. Inside the mitochondria the mitochondrial-localization signal is cleaved 
off, reducing the size of the protein with 5 kDa. VDAC1/Porin (32 kDa) and Lamin B1 (68 kDa) were used as 
mitochondria and nuclear loading controls, respectively.
www.nature.com/scientificreports/
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In the last decades, several dozens of papers have addressed the presence of mtDNA methylation11. In line 
with early reports that reported average mtDNA methylation levels of about 2–5%3, 9, we detected low levels 
of mtDNA methylation. Similarly, a recent study by Liu et al. found only 2 CpGs (out of the 83 analysed) to be 
methylated more than 5%35. Remarkably, these 2 CpGs were both located in the D-loop region, and the one 
investigated in our study, CpG 454 bp, turned out to be the most prominently methylated CpG (varying between 
11–17%) of our study as well. Also two other recent studies confirmed that mtDNA methylation levels are on 
average very low, although regional differences across the mitochondrial genome seem to exist8, 36, with great 
inter-individual differences36. In contrast to all these findings, other recent papers could not confirm the presence 
of mtDNA methylation6, 7. When performing next-generation bisulfite sequencing on DNA from HCT116 cells 
and analysing publicly available genome-wide bisulfite sequencing data from several other DNA sources, Hong et 
al. were unable to detect mtDNA methylation7. Strikingly, the HCT116 cells were the only cell line for which we 
could not detect any methylation either. However, the obtained coverage of 94× the mtDNA may not have been 
sufficient to enable the detection of mtDNA methylation.
Another striking observation from literature, is the relative abundance of cytosine mtDNA methylation 
beyond the CpG context, i.e. CpH methylation. While in the nDNA CpG methylation is most predominant, 
some studies suggest that in the D-loop region of the mtDNA CpH methylation is relatively important13, 15. 
Importantly, by using the appropriate controls, such as replicates, alternative bisulfite procedures, unmethylated 
control samples and samples lacking mtDNA (ρ0 cells), the chance that this high level of CpH methylation could 
be contributed to incomplete bisulfite conversion or the amplification of nuclear copies of mtDNA (NUMTs), was 
minimised. In contrast to these two studies, we observed very low (<1% methylation) levels of CpH methylation 
in all cell lines tested (HCT116, C33A, SKOV3 and HeLa) and in both interrogated regions (D-loop, mtCOX2). 
Such low levels of CpH methylation cannot be distinguished from incomplete bisulfite conversion7, 35. In line with 
our observations, Blanch et al. also detected very low levels of CpH methylation14. Altogether, CpH methylation 
may occur in certain circumstances, but if so, the level and pattern seem to vary by unknown factors.
Figure 5. Normalised mitochondrial gene expression in cells expressing mitochondria-targeted M.SssI or 
M.CviPI. Expression of five (a,b) or six (c,d) mitochondrial genes (mtND1, mtND6, mtCOX1, mtCYTB, 
12S rRNA and 16S rRNA) was determined in stable cell lines of C33A (a) or HCT116 (b) cells expressing 
mitochondria-targeted M.SssI (MLS-M.SssI) or empty vector control (MLS-NoED), and C33A (c) or HCT116 
(d) cells expressing mitochondria-targeted M.CviPI (MLS-M.CviPI) or wild-type cells (wt). Each bar shows the 
mean ± SEM of three independent experiments.
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Despite a very low level of mtDNA methylation, various papers report on a link between mtDNA methyla-
tion and disease11. These studies eluted two possible functions for mtDNA methylation: the regulation of gene 
expression12, 16, 18, 19 and mtDNA replication13, 15. For example, Shock et al. showed that upregulation of mtD-
NMT1 (by p53 knockdown) resulted in increased expression of mtND1, decreased expression of mtND6 and 
unchanged expression of mtATP6 and mtCOX112. However, as p53 knockdown has multiple downstream effects, 
e.g. upregulation of nuclear DNMT1, it is impossible to exclude the possibility that these findings were due to 
indirect effects of the p53 knockdown or due to the increase in nuclear DNMT1 levels. Similarly, in human retinal 
endothelial cells from deceased patients with diabetic retinopathy, the link found between mtDNA methylation 
and repression of certain mtDNA genes18 may well be explained by other factors, including the upregulation of 
nuclear DNMT1 levels. As a consequence, the nuclear DNA of genes involved in mitochondrial biogenesis could 
Figure 6. Normalised mitochondrial DNA copy number of cells expressing mitochondria-targeted M.SssI, 
the catalytically inactive double mutant of M.SssI, or M.CviPI. The effect of mitochondria-targeted M.SssI 
(MLS-M.SssI) or the catalytically inactive double mutant of M.SssI (MLS-M.SssI ∆∆, only for HCT116 cells) 
on mitochondrial DNA copy number normalised to empty vector control (MLS-NoED) was determined in 
stable cell lines of C33A (a) or HCT116 (b). Similarly, the effect of mitochondria-targeted M.CviPI (MLS-M.
CvPI) on mitochondrial DNA copy number normalised to wild-type control (wt) was determined in stable 
cell lines of C33A (c) or HCT116 (d). Each data point represents the mean ± SEM of at least three independent 
experiments.
Figure 7. Expression of nuclear-encoded mitochondrial genes involved in mitochondrial biogenesis in cells 
expressing mitochondria-targeted M.SssI. Expression of four mitochondrial genes (mtND1, mtND6, mtCOX1 
and mtCYTB) was determined in stable cell lines of C33A (a) or HCT116 (b) cells expressing mitochondria-
targeted M.SssI (MLS-M.SssI) or empty vector control (MLS-NoED). Each bar shows the mean ± SEM of three 
independent experiments.
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have been methylated, which would explain the reduction in gene expression. Indeed, it has been described 
in diabetic retinopathy that the mtDNA polymerase POLG becomes hypermethylated and compromises mito-
chondrial transcription37. In contrast to such previously published approaches, our mitochondria-specific 
methylation-induction experiments enabled us to determine any direct downstream consequences of mtDNA 
methylation.
Induction of high levels of CpG methylation by M.SssI decreased the mtDNA copy number in HCT116 cells, 
but not in C33A cells. However, we could not clarify any cellular consequences of this reduction in mtDNA copy 
number for HCT116 cells. In our case, the reduction in mtDNA copy number did not result in a reduction in gene 
expression, as has been proposed to be one of the mechanisms regulating mitochondrial gene expression23, 24. 
Since the study was performed in stable cell lines, mtDNA methylation levels were continuously high. As such, the 
observed reduction in mtDNA copy number may have been either the result of, or an adaptation to survive, the 
high level of methylation. However, if this would have been an adaptive mechanism, we excluded the possibility 
that this was transcriptionally regulated by the master regulator (PGC1α) or other important players (NRF1, 
TFAM) of mitochondrial biogenesis. Alternatively, it was shown that the mtDNA copy number can modulate 
the methylation level of certain nuclear genes38. Interestingly, some of these genes, such as BACH2 and PRKC1B, 
are involved in the regulation of apoptosis in response to oxidative stress. As such, by altering the mtDNA copy 
number, mtDNA methylation may be a way for the mitochondria to communicate to the nucleus in case of e.g. 
environmental stress39, 40. However, in our study we could not find evidence for such a mechanism; the reduced 
mtDNA copy number that was induced by CpG mtDNA methylation did not result in a different sensitivity 
towards ROS-induced cell death.
According to several recent publications, in addition to CpG methylation, CpH methylation may be present 
in the mtDNA13, 15. As such, the induction of GpC methylation, as done by us here, may provide relevant insights 
into a functional role for human mtDNA methylation. In our study, induction of intermediate levels of GpC 
methylation by M.CviPI did not affect mtDNA copy number, but decreased the expression of certain mitochon-
drial genes. Remarkably, both cell lines repressed genes regulated by a different mitochondrial promoter. This 
may point to cell-type specific factors that can affect the outcome of mtDNA methylation. For example, HCT116 
cells are p53 wild-type, whereas C33A cells are p53 mutant. Since p53 is known to repress mtDNMT112, this may, 
via unknown mechanisms, have contributed to the final outcome of mtDNA methylation. Moreover, the mtDNA 
is more actively transcribed (i.e. higher level of mtDNA gene expression per mtDNA molecule) and contains a 
higher level of TFAM in HCT116 cells compared to C33A cells (Suppl. Table 2). As a result, mtDNA methylation 
may have a different outcome depending on these parameters. Although our observations thus point towards 
relevance of GpC methylation, future studies should determine if and how these factors may contribute to the 
functional outcome of mtDNA methylation.
In summary, in this paper we could show that mtDNA CpG methylation, whether it exists or not, did not 
influence gene expression in a similar way as it does for nDNA. If anything, CpH methylation by itself or in 
combination with CpG methylation, might be of direct functional relevance. If this is indeed the case, it may 
have great consequences given the important role of the mitochondria in health and disease41 and the observed 
differential mtDNA methylation profiles in various diseases16–19. However, we do have to remark that the current 
study used an approach that induced mtDNA methylation levels that are far above what has been detected in the 
endogenous situation (2–5% on average)3, 9. As such, the actual physiological relevance of our findings remains 
Figure 8. 7S DNA quantification in mitochondria-targeted M.SssI or M.CviPI. The effect of mitochondria-
targeted M.SssI (MLS-M.SssI) on 7S DNA primer formation normalised to empty vector control (MLS-NoED) 
was determined in stable cell lines of C33A (a) or HCT116 (b). Similarly, the effect of mitochondria-targeted 
M.CviPI (MLS-M.CvPI) on 7S DNA primer formation normalised to wild-type control (wt) was determined in 
stable cell lines of C33A (c) or HCT116 (d). Each data point represents the mean ± SEM of three independent 
experiments.
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to be further studied. Nevertheless, this is the first study that goes beyond the mere description of just another 
association between mtDNA methylation and a specific clinical condition. This study will thus be the start of 
further investigations that address the cause-consequence effects of mtDNA methylation, which are one of the 
necessary next steps to progress our insights into a role of mtDNA methylation. Besides mtDNA methylation, also 
mtDNA hydroxymethylation and post-translational modifications of the mitochondria-localised, histone-like 
protein TFAM have been described10. Such epigenetic-like modifications are reversible and reprogrammable42, 
and hence, this could provide us with new therapeutic targets for many of the aforementioned diseases. Therefore, 
it is essential that future efforts should give us a greater insight in these previously unappreciated epigenetic 
modifications.
Figure 9. Mitochondrial and cellular functions in general in cells expressing mitochondria-targeted M.SssI 
or M.CviPI. In C33A (a,b,c,e,g) and HCT116 (a,b,d,f,h) cells stably expressing mitochondria-targeted M.SssI 
(MLS-M.SssI) or mitochondria-targeted M.CviPI (MLS-M.CviPI) the effect was determined of mtDNA 
methylation on: (a,b) mitochondrial metabolic activity (day 1) and cell proliferation (day 4), as measured by 
MTS; (c–f) mitochondrial superoxide (O2•−) production, as measured with the MitoSox Red ROS probe; (g,h) 
sensitivity toward ROS-induced cell death, as measured with PI. H2O2 was used as a general ROS inducer, 
whereas menadione was used to specifically induce mitochondrial O2•−. Each data point corresponds to the 
mean ± SEM of at least three independent experiments.
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Material and Methods
Cell culture. C33A (human cervical cancer), HCT116 (human colon cancer) and HEK293T (human embryonic 
kidney) cells were obtained from the ATCC. OSE-C2 (immortalised human ovarian epithelial cells43), CiGenCs 
(conditionally immortalised human glomerular endothelial cells44), IHH (immortalised human hepatocytes45) 
and BEAS-2B ρ0 cells (human bronchial epithelium lacking mtDNA) were kindly provided by Dr. Richard 
Edmondson, Dr. Simon Satchell, Dr. Han Moshage and Dr. Roland Hoffmann, respectively.
CiGenCs and IHH were cultured onto gelatin-coated flasks, whereas BEAS-2B ρ0 cells were cultured onto 
collagen-coated flasks. All cell lines, except IHH and BEAS-2B ρ0 cells, were cultured in high glucose (25 mM glu-
cose) DMEM medium (Lonza) supplemented with 10% FCS (Perbio Hyclone), 2 mM L-glutamine (BioWhittaker) 
and 50 μg/mL gentamicin sulfate (Invitrogen). Additionally, the IHH medium contained 20 mU/ml insulin (Novo 
Nordisk) and 50 nmol/L dexamethasone (Sigma). The BEAS-2B ρ0 cells were cultured in high glucose DMEM 
medium supplemented with 25% FCS, 2 mM L-glutamine, 1% P/S, 2.5 μg/ml amphotericin B (Sigma), 1× MEM 
amino acids solution (Sigma), 1× MEM non-essential amino acid solution (Sigma), vitamins (Sigma), 50 μg/ml 
uridine (Sigma). All cells were kept at a humidified incubator with 5% CO2 at 37 °C.
For high versus low glucose treatment, cells were washed twice with PBS and were cultured for 4 days on either 
low (5 mM) or high (25 mM) glucose DMEM.
Cloning. The mitochondria-targeted proteins were all cloned using one “master synthetic construct”. This 
“master synthetic construct” was synthesised at Bio Basic Canada and contains (from 5′- to 3′-end): 1. Kozak 
sequence; 2. N-terminal 49-aa mitochondrial localization signal (MLS) of the F1β subunit of mitochondrial ATP 
synthase46; 3. open position 1; 4. HA-tag; 5. 17-aa flexible linker – (SGGGG)3SS46; 6. open position 2 for epigenetic 
enzyme; 7. C-terminal 18-aa nuclear export signal (NES) of the nonstructural protein 2 of minute virus of mice47; 
8. stopcodon. The addition of restriction enzymes between the individual components enabled flexibility in clon-
ing of the mitochondria-targeted proteins: BamHI – Kozak – MLS – NruI…AvrII – Open position 1 – BsIWI…
NruI – HAtag – flexible linker – EcoRV…AscI – Open position 2 – PacI…EcoRV – NES – stopcodon – NotI. 
This master construct was subcloned into pCDH-CMV-MCS-EF1-copGFP (CD511B-1) using BamHI and NotI 
restriction sites (System Biosciences). In this plasmid EF1-copGFP was swopped with SV40-puromycin resist-
ance using NotI and XhoI restriction enzymes. An additional NES was cloned into the final construct. Moreover, 
the “open position 1” was removed using NruI digestion. For visualization of the plasmid, the same restriction 
enzymes were used to subclone mCherry into “open position 1”. All constructs as described below were cloned 
into this plasmid. As a negative control, a no effector domain (NoED) construct containing no protein in the 
“open position 2”, was generated using EcoRV digestion.
DNMT1. To obtain a PCR product of the mitochondria-targeted DNMT1 transcript variant (mtDNMT1) 
from human reference cDNA (Clontech, random-primed) or a random-primed cDNA pool of human cell lines 
(HEK293T, HCT116, HeLa, IHH, SiHa, Caski, SKOV3, HepG2, C33A, OSE-C2), primers (BclI-mtDNMT1-NotI) 
as described in Table 1 were used. The amplification of mtDNMT1 was unsuccessful, despite the use of a wide 
range of strategies: different DNA polymerases were used according to the manufacturer’s protocol (Phusion 
high-fidelity DNA polymerase (Thermo Scientific), Pfu DNA polymerase (Thermo Scientific), Taq DNA poly-
merase (Thermo Scientific)), the composition of the PCR-mix was varied (buffer type, concentration of MgCl2, 
addition of DMSO), different PCR protocols (melting temperatures, elongation times, number of cycles, etc.) 
were tested. Therefore, as an alternative, the coding sequence of the normal (non-mitochondria-targeted) 
DNMT1 gene (cDNA clone MGC:161505 IMAGE:8991943) was obtained using primers (AscI-DNMT1-PacI) 
as described in Table 1. In order to achieve mitochondria-targeting of DNMT1, this PCR product was cloned 
into pCDH-CMV-master synthetic construct-SV40-puro using AscI and PacI restriction sites, resulting in 
MLS1x-HAtag-flexible linker-DNMT1-2xNES.
M.SssI, M.CviPI, hM.CviPII and the E. coli conII promoter. The plasmid containing M.SssI48 and 
its catalytically inactive double mutant (E186A, R230A), M.SssI∆∆30, were previously obtained from Dr. Antal 
Kiss. Plasmids containing M.CviPI31 and hM.CviPII32 were kindly provided by Dr. Michael Kladde. Before the 
non-human DNA methyltransferases were cloned into pCDH-CMV-master synthetic construct-SV40-puro, the 
E. coli conII promoter was included in the reverse orientation immediately behind the NES. This was done by 
annealing of a complementary pair of oligonucleotides containing conII and digested NotI fragments (Table 1). 
In short, equimolar concentrations of the forward and reverse oligonucleotides were mixed with NEB Buffer 4 
and incubated in a waterbath at 95 °C for 5 min. By turning off the waterbath, the oligonucleotides were allowed to 
slowly cool down to RT. Annealed oligonucleotides were used in subsequent cloning procedures. The convergent 
transcription of conII relative to the DNA methyltransferase gene reduces toxicity due to leaky expression even in 
E. coli strains lacking methylation-dependent restriction49. Subcloning of M.SssI using AscI and PacI restriction 
enzymes, or the PCR product of M.CviPI and hM.CviPII containing AscI and PacI restriction sites enabled the 
generation of the pCDH-CMV-master synthetic construct-conII-SV40-puro containing MLS1x-HAtag-flexible 
linker-(M.SssI/M.CviPI/hM.CviPII)-2x NES. All constructs were confirmed by colony PCR and sequencing 
(Baseclear). Transformation of plasmids containing non-human DNMTs was performed in E. coli ER1821 cells, 
all others were performed in E. coli Top10 cells.
Viral delivery of mitochondria-targeting constructs. Lentiviral particles containing the 
mitochondria-targeting constructs were produced as previously described50. In short, HEK293T packaging cells 
were co-transfected using the calcium phosphate method with plasmids containing the ATF, and viral packaging 
plasmids containing gag/pol and the vesicular stomatitis virus G protein in a 3:2:1 ratio. Viral supernatant was 
collected 48 h and 72 h post transfection and was used in combination with 6 µg/ml polybrene (Sigma-Aldrich) to 
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infect C33A and HCT116 host cells. Three days after transduction, stable cell lines were generated using 1 μg/ml 
puromycin (Sigma) selection for 5 days. Selection medium was refreshed every 2 days.
Validation primers. All primers used to amplify mtDNA were confirmed on agarose gel to specifically 
amplify the mtDNA, and not so-called NUMTs, nuclear copies of mtDNA. For this, the DNA of BEAS-2B ρ0 
cells, containing no mtDNA, was used as negative control. For each q(RT)-PCR primer pair a standard curve was 
generated to calculate the efficiency of the primer pair (Suppl. Fig. 4).
Quantitative real-time PCR (qRT-PCR). Total RNA was isolated using the GeneJET RNA purification kit 
(Thermo Scientific) following manufacturer’s protocol, including an additional 15 minute DNaseI (Roche) treat-
ment to remove DNA contamination. RNA was quantified using a Nanodrop 1000 spectrophotometer (Thermo 
Scientific). 1 µg of RNA was reverse transcribed into cDNA using random hexamer primers with the QuantiTect 
Reverse Transcription Kit (Qiagen), according to manufacturer’s protocol. Each qRT-PCR reaction contained 
500 nM of each primer pair, 10 ng of cDNA and 1xABsolute qPCR SYBR Green, Rox Mix (Thermo Scientific). 
Primers were newly designed, extracted from the Real Time PCR primer Data Bank (RTPrimerDB, http://med-
gen.urgent.be/rtprimerdb/) or obtained from literature23, 51, 52 (Table 1). qRT-PCR reactions were conducted on 
the ViiA7 Real time PCR (Applied Biosystems) for 15 min at 95 °C, followed by 40 cycles of 15 sec at 95 °C, 30 sec 
at 60 °C and 30 sec at 72 °C. β-actin was used as housekeeping gene. Data and melting curves were analysed using 
ViiA7 RUO software and relative expression compared to controls was calculated using the ∆∆Ct method53.
DNA isolation. Cell lysis was performed O/N at 55 °C in TNE lysis buffer (10 mM Tris/HCl, pH 7.5; 150 mM 
NaCl; 10 mM EDTA; 1% SDS) and 100 µg proteinase K. The following day DNA was isolated as described pre-
viously50. In short, lysed cells were mixed for 15 sec. with saturated (6 M) NaCl in a 5:1 ratio. This mixture was 
combined with an equal volume of chloroform/isoamyl alcohol (24: 1) and mixed for 60 min. on a rotor, followed 
by centrifugation for 20 min at 10,000 rpm at 4 °C. Total cellular DNA (genomic and mitochondrial DNA) was 
extracted using chloroform/isoamyl alcohol (24: 1), RNAse A (Thermo Scientific) treated for 1 h at 37 °C, and pre-
cipitated using isopropanol. DNA was quantified using a Nanodrop 1000 spectrophotometer (Thermo Scientific).
Mitochondrial DNA (mtDNA) copy number and 7S DNA primer formation. 10 ng of total cellular 
DNA was used as input for the qPCR. Primers amplifying a nDNA region (β-actin) and a mtDNA region (D-loop) 
were used (Table 1). For validation, an independent mtDNA primer pair of the mtCOX1 region was used. qPCR 
reactions were conducted on the ViiA7 Real time PCR (Applied Biosystems) for 15 min at 95 °C, followed by 40 
cycles of 15 sec at 95 °C, 30 sec at 60 °C and 30 sec at 72 °C. Data and melting curves were analysed using ViiA7 
R U O  s o f t w a r e .  T h e  m t D N A  c o p y  n u m b e r  w a s  d e t e r m i n e d  w i t h  t h e  f o r m u l a : 
−⁎ ⁎2( nDNA mtDNA )Ct primer efficiency Ct primer efficiency 54. To determine the 7S DNA primer formation, primers 
amplifying both the mtDNA and 7S DNA (7S DNA A + B1), or only the mtDNA (7S DNA A + B2) were used 
(Table  1), as described previously15. The level of 7S DNA was calculated with the formula: 
+ − +⁎ ⁎2( 7S DNA A B2 7S DNA A B1 )Ct primer efficiency Ct primer efficiency .
Bisulfite sequencing. 400 ng DNA was bisulfite converted using the EZ DNA methylation Gold kit (Zymo 
Research) according to manufacturer’s instructions. Bisulfite PCR of the D-loop13 and mtCOX27 was performed 
using bisulfite-specific primers (Table 1) as described previously7, 13. PCR products were cloned into pCR4-TOPO 
vector (Thermo Scientific) and individual clones were send for sequencing. Bisulfite sequencing results were ana-
lysed using the online tool QUMA (www.quma.cdb.riken.jp/)55.
Methylated DNA immunoprecipitation (MeDIP). For each immunoprecipitation, 1 µg of total cellular 
DNA was sonicated using the Bioruptor Pico (20 cycles of 20″ on, 40″ off). 5 mC DNA immunoprecipitation was 
performed using the Methylamp methylated DNA capture kit (Epigentek) according to manufacturer’s instruc-
tions. DNA immunoprecipitation using a normal mouse IgG antibody was performed as negative control. The 
enrichment of 5 mC in specific mtDNA regions was analysed using primers for the D-loop, mtCYTB, mtCOX2 (as 
described before in ref. 18, Table 1).
Confocal microscopy. Localization of the mCherry-mitochondria-targeting M.SssI fusion construct was 
visualised using confocal fluorescent microscopy (Leica SP8, HC PL APO CS2 63×/1.4 lens). Following manu-
facturer’s recommendations, to stain the mitochondria, cells were treated with 100 nM Mitotracker Deep Red FM 
(Molecular Probes) for 30 min at 37 °C. The mCherry-mitochondria-targeting M.SssI fusion protein was excited 
using a 552 nm laser light and Mitotracker Deep Red was excited using a 633 nm laser light.
Western blotting. Cells were collected in resuspension buffer (100 mM NaCl, 15 mM MgCl2, 100 mM Tris, 
pH 7.5) and incubated on ice for 10 min while vortexing regularly. Samples were homogenised by flushing the 
cells 5 times through a G25 needle. Subsequently, nuclear (NER) and mitochondrial (MER) protein fractions were 
collected using differential centrifugation56. Protein quantification was performed with the DC BioRad Protein 
Assay (BioRad). 50 µg protein was loaded on a 12% SDS-PAGE gel for the detection of the mitochondria-targeting 
construct (containing a HAtag). Blots were blocked for 1 h with 5% skimmed milk in TBS. For detection, primary 
antibodies were incubated O/N at 4 °C, whereas secondary antibodies were incubated for 1 h at RT. The following 
antibodies were used: 1:1000 mouse anti-HAtag (HA.11, Biolegend), 1:1000 rabbit anti-VDAC1/Porin (Ab34726, 
Abcam), 1:1000 mouse anti-lamin B1 (clone L5, Invitrogen), and 1:1000 horseradish peroxidase-conjugated rab-
bit anti-mouse (P0260, Dako) and swine anti-rabbit (P0217, Dako). Western blot signal was generated with Pierce 
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ECL Plus Western blot substrate (Thermo Scientific) and detected with the Biorad ChemiDoc MP imaging system 
(Biorad).
Mitochondrial metabolic activity. Cells were seeded in 96-wells plates at a density of 3200 cells per well. 
The MTS assay was used to determine mitochondrial metabolic activity and cell proliferation57. In short, one 
day (for the mitochondrial metabolic activity) or four days (for the cell proliferation) after seeding, CellTiter 96 
Aqueous One solution (Promega) was added to each well and incubated for 3 h at 37 °C. Then, the absorbance was 
detected at 490 nm with a Versamax microplate reader (Molecular Devices). When measuring the absorbance 
one day after seeding equal cell numbers, any difference in absorbance can only be explained by a difference in 
mitochondrial metabolic activity, whereas four days after seeding, any difference in absorbance could be the result 
of differences in mitochondrial metabolic activity and cell proliferation/cell viability.
Mitochondrial ROS production. Mitochondrial superoxide levels were determined using the MitoSOX 
Red ROS probe. Cells were washed twice with phenol-red free DMEM, and incubated with 5 μM MitoSOX Red 
in phenol-red free DMEM for 30 min at 37 °C. After treatment, cells were trypsinised and collected for FACS 
measurements (BD LSR-II, BD Biosciences) using a 355 nm UV-laser in combination with a 575/26 nm filter58. 
As a positive control, cells were treated with 100 µM menadione for 1 h at 37 °C.
Cell death analysis. As previously described59, sensitivity toward ROS-induced cell death was determined 
using propidium iodide (PI) as marker for late apoptotic/necrotic cells. Cells were stained for 10 min with 5 μg/
mL PI (Sigma-Aldrich) in PBS at 4 °C in the dark. PI fluorescence was measured using the FL-3 channel of a 
FACScalibur flow cytometer (Beckton Dickenson Biosciences). The percentage of PI positive cells was deter-
mined with Kaluza 1.2 (Beckman Coulter) software and graphs were made using Graphpad Prism 5 software 
(GraphPad Software Inc.).
Statistical analysis. All experiments were performed three times, unless stated otherwise. Statistical anal-
ysis was performed using Graphpad Prism 5 software. Single group and multiple group comparisons were per-
formed with the student’s t-test or one-way ANOVA followed by Dunnett’s post hoc test, respectively. A p-value 
of 0.05 or less was considered statistical significant (*p ≤ 0.05, **p < 0.01 and ***p < 0.001).
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